190.00 +1.81 (0.96%)
Pre-market: 5:51AM EST
|Bid||188.19 x 800|
|Ask||0.00 x 1100|
|Day's range||187.82 - 190.39|
|52-week range||114.27 - 194.61|
|Beta (5Y monthly)||1.64|
|PE ratio (TTM)||N/A|
|Earnings date||02 Feb 2020 - 06 Feb 2020|
|Forward dividend & yield||2.96 (1.54%)|
|Ex-dividend date||11 Nov 2019|
|1y target est||190.14|
Despite all the positivity, investors should think about adding a few large-cap stocks that pay a solid dividend to help anchor their portfolios in 2020...
Aclaris (ACRS) announces favorable preliminary data from the phase I study on its investigational candidate ATI-450, presently being developed for treating immuno-inflammatory diseases. Stock rises.
Editas (EDIT) progresses well on developing its lead candidate EDIT-101 to treat LCA10, a rare genetic illness that causes blindness. Excessive reliance on partners for revenues remains a concern.